CA2163716A1 - Verotoxin pharmaceutical compositions and medical treatments therewith - Google Patents
Verotoxin pharmaceutical compositions and medical treatments therewithInfo
- Publication number
- CA2163716A1 CA2163716A1 CA002163716A CA2163716A CA2163716A1 CA 2163716 A1 CA2163716 A1 CA 2163716A1 CA 002163716 A CA002163716 A CA 002163716A CA 2163716 A CA2163716 A CA 2163716A CA 2163716 A1 CA2163716 A1 CA 2163716A1
- Authority
- CA
- Canada
- Prior art keywords
- verotoxin
- pharmaceutical compositions
- medical treatments
- cancer
- verotoxins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1 and their pentameric subunit B, have been found to be useful in the treatment of mammalian neoplasia, particularly, brain cancer, ovarian cancer, breast cancer and skin cancer. Although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti- neoplastic in vivo. Use of a sensitizer, such as sodium butyrate, enhances the efficacy of verotoxins and their subunit B.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002163716A CA2163716C (en) | 1995-11-24 | 1995-11-24 | Verotoxin pharmaceutical compositions and medical treatments therewith |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002163716A CA2163716C (en) | 1995-11-24 | 1995-11-24 | Verotoxin pharmaceutical compositions and medical treatments therewith |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2163716A1 true CA2163716A1 (en) | 1997-05-25 |
CA2163716C CA2163716C (en) | 2009-05-19 |
Family
ID=4157034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002163716A Expired - Fee Related CA2163716C (en) | 1995-11-24 | 1995-11-24 | Verotoxin pharmaceutical compositions and medical treatments therewith |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2163716C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998051326A1 (en) * | 1997-05-16 | 1998-11-19 | Hsc Research And Development Limited Partnership | Inhibition of angiogenesis by verotoxins |
WO1999038530A1 (en) * | 1998-01-28 | 1999-08-05 | University Of Bristol | Agent capable of modulating a glycosphingolipid-associated activity thus affecting an immune disorder |
WO2000029556A2 (en) * | 1998-11-17 | 2000-05-25 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of glycosphingolipids that promote hiv-1 entry into cells |
US7846435B1 (en) | 1998-05-20 | 2010-12-07 | Teijin Limited | Humanized antibodies that recognize Verotoxin II and cell line producing same |
-
1995
- 1995-11-24 CA CA002163716A patent/CA2163716C/en not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998051326A1 (en) * | 1997-05-16 | 1998-11-19 | Hsc Research And Development Limited Partnership | Inhibition of angiogenesis by verotoxins |
WO1999038530A1 (en) * | 1998-01-28 | 1999-08-05 | University Of Bristol | Agent capable of modulating a glycosphingolipid-associated activity thus affecting an immune disorder |
US7846435B1 (en) | 1998-05-20 | 2010-12-07 | Teijin Limited | Humanized antibodies that recognize Verotoxin II and cell line producing same |
WO2000029556A2 (en) * | 1998-11-17 | 2000-05-25 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of glycosphingolipids that promote hiv-1 entry into cells |
WO2000029556A3 (en) * | 1998-11-17 | 2000-11-23 | Us Health | Identification of glycosphingolipids that promote hiv-1 entry into cells |
Also Published As
Publication number | Publication date |
---|---|
CA2163716C (en) | 2009-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9406893A (en) | Use of ninth- and decapeptides for the preparation of a medicine to fight AIDS | |
CA2122612A1 (en) | Pharmaceutical products for curing tumourous diseases and process for preparing same | |
AU8469498A (en) | Peptide derivatives or pharmaceutically acceptable salts thereof, method for producing the same, use of said derivatives and pharmaceutical composition | |
HUT71835A (en) | Itraconazole and saperconazole stereoisomers, their cyclodextrin complexes and pharmaceutical compositions containing them and process for producing them | |
MX9302038A (en) | METHOD FOR THE TREATMENT OF CANCER BY A JOINT THERAPY WITH 2-HALOMETILIDENO DERIVATIVES AND A SPECIFIC PHASE M OR PHASE S ANTINEOPLASIC AGENT. | |
CA2373794A1 (en) | Compositions and uses of et743 for treating cancer | |
MY107088A (en) | Plaster used as therapeutic system for the administration of active substances to the skin, which exhibits a graduated active substance release,process for the production of the plaster and use thereof | |
RU95103892A (en) | COMPOSITION FOR TOPIC APPLICATION FOR HAIR GROWTH STIMULATION AND/OR THEIR FALLING OUT RETARDATION, METHOD OF COSMETIC HAIR TREATMENT, USE OF α-PYRONE DERIVATIVE FOR COMPOSITION PREPARING | |
RS50692B (en) | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer | |
WO2000072823A8 (en) | Preparations for the application of anti-inflammatory agents | |
GEP20043202B (en) | Resorcinol Derivatives | |
CA2163716A1 (en) | Verotoxin pharmaceutical compositions and medical treatments therewith | |
WO2000008007A3 (en) | Cyclopentabenzofuran derivatives and their use | |
CA2116179A1 (en) | Verotoxin pharmaceutical compositions and medical treatments therewith | |
AU5691796A (en) | Terpenoidic derivatives useful as antitumor agents | |
MX9203405A (en) | ACTIVE COMPOUNDS TO BE USED IN THE TREATMENT OF TUMORS. | |
TR200401810T4 (en) | Use of fsh for infertility treatment | |
GB9505082D0 (en) | Medicament | |
GR3034062T3 (en) | Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease | |
IL135171A0 (en) | Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye | |
IT8448710A1 (en) | REDUCTION OF TOXIC EFFECTS CAUSED BY ANTHRACHINONIC DRUGS | |
KR950023398A (en) | Beauty bamboo salt | |
RU94003538A (en) | A METHOD OF INCREASING THE EFFICIENCY OF RADIOTHERAPY THERAPY | |
IT1265649B1 (en) | Dermatological product for topical use, corresponding production process and therapeutic use in skin burns and diseases | |
RU96110391A (en) | METHOD FOR TREATING EYE BURNS AND TRAUMATIC EROSIONS OF THE CORNEA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20151124 |